The Effects of ATIR Blocker on the Severity of COVID-19 in Hypertensive Inpatients and Virulence of SARS-CoV-2 in Hypertensive hACE2 Transgenic Mice.
The Effects of ATIR Blocker on the Severity of COVID-19 in Hypertensive Inpatients and Virulence of SARS-CoV-2 in Hypertensive hACE2 Transgenic Mice.
复制标题
DOI:
10.1007/s12265-021-10147-3
复制
发表时间:
2022-03
影响因子:
3.4
通讯作者:
Yang Z
中科院分区:
文献类型:
--
作者:
Jiang X;Li H;Liu Y;Bao L;Zhan L;Gao H;Deng W;Xue J;Liu J;Liu X;Li J;Wang J;Wu S;Yan M;Luo W;Jose PA;Qin C;Yang X;Zhang D;Yang Z
Angiotensin-converting enzyme 2 (ACE2) is required for the cellular entry of the severe acute respiratory syndrome coronavirus 2. ACE2, via the Ang-(1-7)-Mas-R axis, is part of the antihypertensive and cardioprotective effects of the renin-angiotensin system. We studied hospitalized COVID-19 patients with hypertension and hypertensive human(h) ACE2 transgenic mice to determine the outcome of COVID-19 with or without AT1 receptor (AT1R) blocker treatment. The severity of the illness and the levels of serum cardiac biomarkers (CK, CK-BM, cTnI), as well as the inflammation markers (IL-1, IL-6, CRP), were lesser in hypertensive COVID-19 patients treated with AT1R blockers than those treated with other antihypertensive drugs. Hypertensive hACE2 transgenic mice, pretreated with AT1R blocker, had increased ACE2 expression and SARS-CoV-2 in the kidney and heart, 1 day post-infection. We conclude that those hypertensive patients treated with AT1R blocker may be at higher risk for SARS-CoV-2 infection. However, AT1R blockers had no effect on the severity of the illness but instead may have protected COVID-19 patients from heart injury, via the ACE2-angiotensin1-7-Mas receptor axis. The online version contains supplementary material available at 10.1007/s12265-021-10147-3.
登录
查看更多内容
影响因子:
19.6
作者:
Cheng, Yichun;Luo, Ran;Xu, Gang
通讯作者:
Xu, Gang
影响因子:
24
作者:
Inciardi, Riccardo M.;Lupi, Laura;Metra, Marco
通讯作者:
Metra, Marco
影响因子:
158.5
作者:
Mancia, Giuseppe;Rea, Federico;Corrao, Giovanni
通讯作者:
Corrao, Giovanni
DOI:
10.1136/heartjnl-2020-317393
发表时间:
2020-10
期刊:
Heart (British Cardiac Society)
影响因子:
--
作者:
Hippisley-Cox J;Young D;Coupland C;Channon KM;Tan PS;Harrison DA;Rowan K;Aveyard P;Pavord ID;Watkinson PJ
通讯作者:
Watkinson PJ
影响因子:
8.3
作者:
Iaccarino, Guido;Grassi, Guido;Volpe, Massimo
通讯作者:
Volpe, Massimo